S0502 Adverse Event Form S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder:

  1. 9/19/12 9/19/12 -
  2. 1/8/15 1/8/15 - Martin Dugas
  3. 1/9/15 1/9/15 - Martin Dugas
  4. 1/9/15 1/9/15 - Martin Dugas
Uploaded on:

January 9, 2015

To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Gastrointestinal Stromal Tumor NCT00324987 Toxicity - S0502 Adverse Event Form - 2320351v1.0

Intergroup Coalition Against Sarcomas (ICAS)

  1. StudyEvent: S0502 Adverse Event Form
    1. Intergroup Coalition Against Sarcomas (ICAS)
Adverse Events
Were adverse events assessed during this time period?
CTC Adverse Event Term
CTC Adverse Event Attribution Code (* Attribution codes: 1-unrelated 2-unlikely 3-possible 4-probably 5-definite)
Adverse event status code (** Status codes since baseline or last cycle: 1-new 2-continues at same or lower grade 3-increased grade OR improved then worsened)

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial